Featured Tickers:
Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Baxter International Inc. or PROCEPT BioRobotics Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Baxter International Inc. and PROCEPT BioRobotics Corporation compare based on key financial metrics to determine which better meets your investment needs.
About Baxter International Inc. and PROCEPT BioRobotics Corporation
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Latest Health Care Equipment & Supplies and Baxter International Inc., PROCEPT BioRobotics Corporation Stock News
As of December 5, 2025, Baxter International Inc. had a $9.5 billion market capitalization, compared to the Health Care Equipment & Supplies median of $323.2 million. Baxter International Inc.’s stock is down 37.7% in 2025, down 4.8% in the previous five trading days and down 44.04% in the past year.
Currently, Baxter International Inc. does not have a price-earnings ratio. Baxter International Inc.’s trailing 12-month revenue is $11.0 billion with a -3.1% net profit margin. Year-over-year quarterly sales growth most recently was 5.0%. Analysts expect adjusted earnings to reach $2.364 per share for the current fiscal year. Baxter International Inc. currently has a 0.2% dividend yield.
As of December 5, 2025, PROCEPT BioRobotics Corporation had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. PROCEPT BioRobotics Corporation’s stock is down 57.7% in 2025, up 11.9% in the previous five trading days and down 62.83% in the past year.
Currently, PROCEPT BioRobotics Corporation does not have a price-earnings ratio. PROCEPT BioRobotics Corporation’s trailing 12-month revenue is $299.9 million with a -28.2% net profit margin. Year-over-year quarterly sales growth most recently was 42.6%. Analysts expect adjusted earnings to reach $-1.510 per share for the current fiscal year. PROCEPT BioRobotics Corporation does not currently pay a dividend.
How We Compare Baxter International Inc. and PROCEPT BioRobotics Corporation Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Baxter International Inc. and PROCEPT BioRobotics Corporation’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions